Upcoming biologic agents for the treatment of rheumatic diseases

被引：45

作者：

Shanahan, JC ^{[1
]}

Moreland, LW ^{[1
]}

Carter, RH ^{[1
]}

机构：

[1] Univ Alabama Birmingham, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA

来源：

CURRENT OPINION IN RHEUMATOLOGY | 2003年 / 15卷 / 03期

关键词：

D O I：

10.1097/00002281-200305000-00009

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The development of biologic agents has provided rheumatologists with a variety of new and effective treatment options. The success of early biologics, especially etanercept and infliximab for the treatment of rheumatoid arthritis, has spurred research into novel targets for the management of systemic inflammatory and autoimmune diseases. In addition, existing biologics approved for use in other diseases, such as rituximab, are now under study for the treatment of new indications. This article reviews ongoing research on the treatment of rheumatic diseases with new and existing biologic agents.

引用

页码：226 / 236

页数：11

共 126 条

[71] A multicenter dose-escalation trial with denileukin diftitox (ONTAK, DAB389 IL-2) in patients with severe psoriasis [J].

Martin, A ;

Gutierrez, E ;

Muglia, J ;

McDonald, CJ ;

Guzzo, C ;

Gottlieb, A ;

Pappert, A ;

Garland, WT ;

Bagel, J ;

Bacha, P .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2001, 45 (06) :871-881

[72]

Matsuno H, 2002, J RHEUMATOL, V29, P1609

[73] IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis [J].

McInnes, IB ;

Illei, GG ;

Danning, CL ;

Yarboro, CH ;

Crane, M ;

Kuroiwa, T ;

Schlimgen, R ;

Lee, E ;

Foster, B ;

Flemming, D ;

Prussin, C ;

Fleisher, TA ;

Boumpas, DT .

JOURNAL OF IMMUNOLOGY, 2001, 167 (07) :4075-4082

[74] Pre-treatment affinity for LJP 394 influences pharmacodynamic response in lupus patients [J].

McNeeley, PA ;

Iverson, GM ;

Furie, RA ;

Cash, JM ;

Cronin, ME ;

Katz, RS ;

Weisman, MH ;

Aranow, C ;

Linnik, MD .

LUPUS, 2001, 10 (08) :526-532

[75] Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis [J].

Moreland, L ;

Gugliotti, R ;

King, K ;

Chase, W ;

Weisman, M ;

Greco, T ;

Fife, R ;

Korn, J ;

Simms, R ;

Tesser, J ;

Hillson, J ;

Caldwell, J ;

Schnitzer, T ;

Lyons, D ;

Schwertschlag, U .

ARTHRITIS RESEARCH, 2001, 3 (04) :247-252

[76] Costimulatory blockade in patients with rheumatoid arthritis a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion [J].

Moreland, LW ;

Alten, R ;

Van den Bosch, F ;

Appelboom, T ;

Leon, M ;

Emery, P ;

Cohen, S ;

Luggen, M ;

Shergy, W ;

Nuamah, I ;

Becker, JC .

ARTHRITIS AND RHEUMATISM, 2002, 46 (06) :1470-1479

[77]

Newton RC, 2001, ANN RHEUM DIS, V60, pIII25

[78] INSITU PRODUCTION OF TNF-ALPHA, IL-1-BETA AND IL-2R IN ANCA-POSITIVE GLOMERULONEPHRITIS [J].

NORONHA, IL ;

KRUGER, C ;

ANDRASSY, K ;

RITZ, E ;

WALDHERR, R .

KIDNEY INTERNATIONAL, 1993, 43 (03) :682-692

[79]

Ogawa Y, 2002, ARTHRITIS RHEUM-US, V46, pS210

[80] PPA250 [3-(2,4-difluorophenyl)-6-{2-[4-(1H-imidazol-1-ylmethyl)phenoxy]ethoxy}-2-phenylpyridine], a novel orally effective inhibitor of the dimerization of inducible nitric-oxide synthase, exhibits an anti-inflammatory effect in animal models of chronic arthritis [J].

Ohtsuka, M ;

Konno, F ;

Honda, H ;

Oikawa, T ;

Ishikawa, M ;

Iwase, N ;

Isomae, K ;

Ishii, F ;

Hemmi, H ;

Sato, S .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 303 (01) :52-57

← 3 4 5 6 7 8 9 10 11 12 →